首页> 外文期刊>Genes, Chromosomes and Cancer >Determination of the mutant allele frequency in patients with neurofibromatosis type 2 and somatic mosaicism by means of deep sequencing
【24h】

Determination of the mutant allele frequency in patients with neurofibromatosis type 2 and somatic mosaicism by means of deep sequencing

机译:深度测序法测定2型神经纤维瘤病和体细胞镶嵌症患者的突变等位基因频率

获取原文
获取原文并翻译 | 示例
           

摘要

Neurofibromatosis Type 2 (NF2) is an autosomal disorder caused by mutations of the NF2 gene. More than half of all NF2 patients have unaffected parents and carry de novo mutations, which may be of prezygotic or postzygotic origin. The latter can result in mosaicism, which is relatively common in NF2 patients. Previous studies indicated that, in 50% of patients with mosaic NF2 mutations, the mutant allele is only detectable by Sanger sequencing of PCR products amplified from tumor tissue but not from blood samples. In order to establish a highly sensitive method that has the power to detect low levels of NF2 mutant alleles from blood samples of mosaic NF2 patients, we performed ultra deep sequencing and calculated the percentage of mutant and wildtype NF2 alleles. The mutant allele frequencies detected ranged from 2.6% to 19.7%. In three patients, however, the NF2 mutation previously identified in tumor tissue was not identified in blood samples by means of deep sequencing, suggesting absence of mutant cells in the blood. Remarkably, we observed a correlation between the age at onset of the disease and the mutant allele frequency. Our study indicates that ultra deep sequencing is an effective and highly sensitive method to determine the mutant allele frequency in patients with mosaic NF2 gene mutations, which enables extended phenotype/correlations in these patients. (c) 2015 Wiley Periodicals, Inc.
机译:2型神经纤维瘤病(NF2)是由NF2基因突变引起的常染色体疾病。在所有NF2患者中,有超过一半的父母没有受到影响,并且携带了从头突变,这些突变可能来自合子前或合子后。后者可导致镶嵌,这在NF2患者中相对常见。先前的研究表明,在50%的具有镶嵌NF2突变的患者中,只有通过从肿瘤组织扩增而来的PCR产物的Sanger测序才能检测到突变等位基因,而从血液样本中无法检测到。为了建立一种高灵敏度的方法,该方法能够从镶嵌NF2患者的血液样本中检测出低水平的NF2突变等位基因,我们进行了超深度测序并计算了突变型和野生型NF2等位基因的百分比。检测到的突变等位基因频率范围为2.6%至19.7%。然而,在三名患者中,先前在肿瘤组织中鉴定出的NF2突变没有通过深度测序在血样中鉴定出来,这表明血液中没有突变细胞。值得注意的是,我们观察到该病发病年龄与突变等位基因频率之间的相关性。我们的研究表明,超深度测序是一种确定镶嵌NF2基因突变患者突变等位基因频率的有效且高度灵敏的方法,可以使这些患者扩展表型/相关性。 (c)2015年威利期刊有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号